Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar 31:6:53.
doi: 10.3389/fnagi.2014.00053. eCollection 2014.

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease

Affiliations

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease

Lucilla Parnetti et al. Front Aging Neurosci. .

Abstract

There is a great interest in developing cerebrospinal fluid (CSF) biomarkers for diagnosis and prognosis of Parkinson's disease (PD). CSF alpha synuclein (α-syn) species, namely total and oligomeric α-syn (t-α-syn and o-α-syn), have shown to be of help for PD diagnosis. Preliminary evidences show that the combination of CSF t-α-syn and classical Alzheimer's disease (AD) biomarkers-β-amyloid 1-42 (Aβ42), total tau (t-tau), phosphorylated tau (p-tau)-differentiate PD patients from controls, and that reduced levels of Aβ42 represent a predictive factor for development of cognitive deterioration in PD. In this prospective study carried out in 44 PD patients and 25 neurological controls we wanted to verify whether the combination of CSF α-synuclein species-t-α-syn and o-α-syn-and classical AD biomarkers may help in differentiating PD from neurological controls, and if these biomarkers may predict cognitive decline. The median of follow-up duration was 3 years (range: 2-6 years). Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) were used for monitoring cognitive changes along time, being administered once a year. Oligo/total α-syn ratio (o/t-α-syn ratio) confirmed its diagnostic value, significantly contributing to the discrimination of PD from neurological controls. A greater diagnostic accuracy was reached when combining o/t-α-syn and Aβ42/tau ratios (Sens = 0.70, Spec = 0.84, AUC = 0.82; PPV = 0.89, NPV = 0.62, LR+ = 4.40, DOR = 12.52). Low CSF Aβ42 level was associated with a higher rate of MMSE and MoCA decline, confirming its role as independent predictive factor for cognitive decline in PD. None of the other biomarkers assessed (t-tau, p-tau, t-α-syn and o-α-syn) showed to have prognostic value. We conclude that combination of CSF o/t-α-syn and Aβ42/tau ratios improve the diagnostic accuracy of PD. PD patients showing low CSF Aβ42 levels at baseline are more prone to develop cognitive decline.

Keywords: Aβ42; Parkinson's disease; alpha synuclein; cerebrospinal fluid biomarkers; cognitive decline; phosphorylated tau; total tau.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Boxplots of CSF biomarkers values observed in PD and OND cohorts. The horizontal bold lines indicate the medians; the lower part of boxes indicates the first quartile and the upper part the third quartile; the dashed vertical lines indicate the range of values.
Figure 2
Figure 2
42/t-tau and o/t-α-syn ratios in PD and OND. (A) Scatterplot: the dashed line represents a partition of the o/t-α-syn and Aβ42/t-tau space such that below the line the model predicts OND, above the line the model predicts PD (B) ROC curves of Aβ42/t-tau and o/t-α syn ratios and the fitted values of the multivariable logistic regression model.

References

    1. Aerts M. B., Esselink R. A., Abdo W. F., Bloem B. R., Verbeek M. M. (2012). CSF α-synuclein does not differentiate between parkinsonian disorders. Neurobiol. Aging 33, 430.e1–430.e3 10.1016/j.neurobiolaging.2010.12.001 - DOI - PubMed
    1. Alves G., Brønnick K., Aarsland D., Blennow K., Zetterberg H., Ballard C., et al. (2010). CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J. Neurol. Neurosurg. Psychiatry 81, 1080–1086 10.1136/jnnp.2009.199950 - DOI - PubMed
    1. Balducci C., Pierguidi L., Persichetti E., Parnetti L., Sbaragli M., Tassi C., et al. (2007). Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease. Mov. Disord. 22, 1481–1484 10.1002/mds.21399 - DOI - PubMed
    1. Braak H., Del Tredici K., Rüb U., de Vos R. A., Jansen Steur E. N., Braak E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197–211 10.1016/S0197-4580(02)00065-9 - DOI - PubMed
    1. Ciaccioli G., Martins A., Rodrigues C., Vieira H., Calado P. (2013). A powerful yeast model to investigate the synergistic interaction of α-synuclein and tau in neurodegeneration. PLoS ONE 8:e55848 10.1371/journal.pone.0055848 - DOI - PMC - PubMed

LinkOut - more resources